BeOne Medicines (ONC) Stock: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$358.07
-0.70 (-0.20%)
▼
5d:
-0.77%
30d:
-1.03%
90d:
+15.71%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ONC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ONC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$498.95
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$309.81
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $358.07, which is considered fair relative to its 30-day fair value range of $351.23 to $368.94. The stock's valuation (Forward PE: 34.9) is in line with its historical norms (36.9). Remarkably, the market is currently pricing in an annual earnings decline of 1.8% over the next few years. This pessimistic expectation contrasts with the company's recent 166.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a strong uptrend. The price is currently testing key support at $349.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $433.52 (+21.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ONC is in a strong uptrend. The price is currently testing key support at $349.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $433.52 (+21.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$351.23 -
$368.94
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.1% below Wall St target ($433.52)
- NEUTRAL: Bottoming setup forming (42/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$351.23 -
$368.94
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$349.74
Resistance Level
$376.50
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
34.94
Wall Street Target
$433.52
(+21.1%)
Revenue Growth (YoY)
29.6%
Earnings Growth (YoY)
166.7%
Profit Margin
10.7%
Valuation Discount vs History
-1.8% cheaper
PE vs Historical
34.9 vs 36.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.8%
(market-implied from PE analysis)
1-Year Target
$351.62
(-2%)
2-Year Target
$345.30
(-4%)
3-Year Target
$339.08
(-5%)
3-Yr Target (if PE normalizes)
(PE: 35→37)
$358.12
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 34.9, Growth: 34.4%)
$869.91
(+143%)
Base:
(SPY PE: 20.4, Growth: 34.4%)
$507.93
(+42%)
Bear:
(PE: 17.3, Growth: 34.4%)
$431.74
(+21%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (35x PE), but valuation improves significantly next year (35x PE) as earnings recover.
Forward PE: 35.21 | Forward EPS (Implied): $10.17
Bull Case
$432.37
(+21%)
Analyst growth 15.0%, PE expands to 37.0
Base Case
$358.07
(0%)
Market implied 0.0%, PE stable at 35.2
Bear Case
$273.92
(-24%)
Severe decline -15.0%, PE contracts to 31.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 34.9 to 36.9
Stabilization Target:
$378.18
(+5.6%)
PE Expansion Potential:
+5.6%
Share & Embed Analysis
Last updated: October 02, 2026 6:58 PM ET
Data refreshes hourly during market hours. Next update: 7:58 PM
Data refreshes hourly during market hours. Next update: 7:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 52 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$107 | 67 BUY |